3-Hydroxy-Propanamine Derived Neuronal Reuptake Inhibitors
- Summary
- Antidepressants such as Prozac, Paxil and Zoloft, are characterized by an ability to selectively block reuptake of serotonin (5-HT). Selective NE-reuptake inhibitor antidepressants such as Tomoxetine and Vivalan have also been developed. Effexor and Serzone have been termed SNRI antidepressants because they inhibit 5-HT and NE reuptake with similar potency. However, these present drugs are ineffective to some patients. Only new generation of drugs possess reuptake inhibition profile different from those currently known can solve the problem.
The invention relates to the new class of antidepressant compounds, which exhibit synaptosomal reuptake inhibition of neurotransmitters such as serotonin (5-HT), norephinephrine (NE), and dopamin (DA) simultaneously. These new compounds possess special reuptake inhibition profile. The antidepressant properties of these compounds were assayed. The best of these new compounds bind to the transporter protein 175 times stronger than serotonin itself. These compounds will therefore effectively block synaptosomal reuptake of serotonin.
- Technology Benefits
- 1. Comparatively reduced therapeutic dosages of antidepressant compounds
2. Less side effects
3. More effective
4. Wide range of usage
- Technology Application
- - New antidepressant drugs
- Supplementary Information
- Patent Number: US6069177A
Application Number: US1997889357A
Inventor: Carlier, Paul R. | Richelson, Elliott | Lo, Ching Kam | Lo, Man Chu
Priority Date: 8 Jul 1997
Priority Number: US6069177A
Application Date: 8 Jul 1997
Publication Date: 30 May 2000
IPC Current: C07C021528
US Class: 514652 | 564349
Assignee Applicant: The Hong Kong University of Science & Technology
Title: 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
Usefulness: 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
Summary: USE The derivative represents a kind of new-type mental state therapeutic medicine as antidepressant.
Novelty: 3-hydroxyl-propylamide derived nerve cell reabsorption inhibitor useful as a new-type mental state therapeutic medicine as a antidepressant
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application Date
- 8 Jul 1997
- Application No.
- US 08/889357
- Patent Information
- US 6069177
- ID No.
- TTC.PA.052
- Country/Region
- Hong Kong
For more information, please click Here
